ATE384740T1 - Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose - Google Patents
Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptoseInfo
- Publication number
- ATE384740T1 ATE384740T1 AT03809607T AT03809607T ATE384740T1 AT E384740 T1 ATE384740 T1 AT E384740T1 AT 03809607 T AT03809607 T AT 03809607T AT 03809607 T AT03809607 T AT 03809607T AT E384740 T1 ATE384740 T1 AT E384740T1
- Authority
- AT
- Austria
- Prior art keywords
- apoptosis
- eif
- specific eif
- polypeptides
- tissue
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000006907 apoptotic process Effects 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 abstract 5
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 abstract 5
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 abstract 4
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000005003 heart tissue Anatomy 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/277,969 US7217517B2 (en) | 2001-07-23 | 2002-10-23 | Nucleic acids, polypeptides, and methods for modulating apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384740T1 true ATE384740T1 (de) | 2008-02-15 |
Family
ID=32174556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03809607T ATE384740T1 (de) | 2002-10-23 | 2003-10-22 | Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7217517B2 (enExample) |
| EP (1) | EP1578452B1 (enExample) |
| JP (1) | JP4890763B2 (enExample) |
| KR (1) | KR20050046015A (enExample) |
| CN (1) | CN1732018B (enExample) |
| AT (1) | ATE384740T1 (enExample) |
| AU (1) | AU2003301585B2 (enExample) |
| CA (1) | CA2503442C (enExample) |
| DE (1) | DE60318900D1 (enExample) |
| NZ (1) | NZ540105A (enExample) |
| TW (1) | TWI324070B (enExample) |
| WO (1) | WO2004037984A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166467B2 (en) * | 2001-07-23 | 2007-01-23 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| NZ542665A (en) * | 2003-03-05 | 2008-05-30 | Senesco Technologies Inc | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| US20140371299A1 (en) * | 2004-06-07 | 2014-12-18 | Senesco Technologies, Inc. | Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis |
| AR049999A1 (es) * | 2004-07-20 | 2006-09-20 | Senesco Technologies Inc | Uso de siarn de eif-5a y polinucleotidos antisentido especificos de la apoptosis para inhibir/suprimir una respuesta inflamatoria. |
| EP1959010A3 (en) * | 2004-12-03 | 2009-02-25 | Senesco Technologies, Inc. | Apoptosis-specific eif-5A and polynucleotides encoding same |
| JP5205058B2 (ja) * | 2004-12-03 | 2013-06-05 | セネスコ テクノロジーズ，インコーポレイティド | 種子の収量を増大させる方法 |
| WO2009144933A1 (ja) * | 2008-05-27 | 2009-12-03 | 国立大学法人東京大学 | アポトーシス誘導薬 |
| JP6639408B2 (ja) | 2014-11-07 | 2020-02-05 | 藤倉化成株式会社 | デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法 |
| JP2021526837A (ja) * | 2018-06-12 | 2021-10-11 | アンジーエックス・インコーポレーテッド | 抗体−オリゴヌクレオチドコンジュゲート |
| CN114231551B (zh) * | 2021-12-24 | 2023-09-29 | 云南大学 | 蛋白在促进昆虫淋巴细胞凋亡和/或防治害虫中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| CZ255397A3 (cs) * | 1995-02-13 | 1998-02-18 | Novartis Ag | Mutantní proteiny, způsob jejich přípravy, farmaceutické prostředky, které je obsahují, a jejich použití |
| US5849587A (en) | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| WO1999001551A2 (en) | 1997-06-30 | 1999-01-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel inhibitor of cellular proliferation |
| US6538182B1 (en) | 1999-07-06 | 2003-03-25 | Senesco, Inc. | DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants |
| WO2001010906A1 (en) | 1999-08-06 | 2001-02-15 | Pharmacia & Upjohn Company | Crystallization and structure determination of staphylococcus aureus elongation factor p |
| US7166467B2 (en) | 2001-07-23 | 2007-01-23 | Senesco Technologies, Inc. | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
-
2002
- 2002-10-23 US US10/277,969 patent/US7217517B2/en not_active Expired - Fee Related
-
2003
- 2003-10-22 NZ NZ540105A patent/NZ540105A/en unknown
- 2003-10-22 CA CA2503442A patent/CA2503442C/en not_active Expired - Fee Related
- 2003-10-22 KR KR1020057006733A patent/KR20050046015A/ko not_active Ceased
- 2003-10-22 JP JP2004547020A patent/JP4890763B2/ja not_active Expired - Fee Related
- 2003-10-22 AU AU2003301585A patent/AU2003301585B2/en not_active Ceased
- 2003-10-22 AT AT03809607T patent/ATE384740T1/de not_active IP Right Cessation
- 2003-10-22 DE DE60318900T patent/DE60318900D1/de not_active Expired - Lifetime
- 2003-10-22 EP EP03809607A patent/EP1578452B1/en not_active Expired - Lifetime
- 2003-10-22 WO PCT/US2003/033463 patent/WO2004037984A2/en not_active Ceased
- 2003-10-22 CN CN200380107399.3A patent/CN1732018B/zh not_active Expired - Fee Related
- 2003-10-23 TW TW092129428A patent/TWI324070B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2503442C (en) | 2014-02-18 |
| EP1578452A4 (en) | 2006-01-11 |
| TW200501988A (en) | 2005-01-16 |
| AU2003301585B2 (en) | 2009-08-20 |
| WO2004037984A3 (en) | 2005-04-14 |
| CN1732018A (zh) | 2006-02-08 |
| EP1578452A2 (en) | 2005-09-28 |
| CN1732018B (zh) | 2014-09-10 |
| US20030144238A1 (en) | 2003-07-31 |
| CA2503442A1 (en) | 2004-05-06 |
| NZ540105A (en) | 2006-10-27 |
| DE60318900D1 (de) | 2008-03-13 |
| US7217517B2 (en) | 2007-05-15 |
| EP1578452B1 (en) | 2008-01-23 |
| AU2003301585A1 (en) | 2004-05-13 |
| JP4890763B2 (ja) | 2012-03-07 |
| KR20050046015A (ko) | 2005-05-17 |
| TWI324070B (en) | 2010-05-01 |
| JP2006507816A (ja) | 2006-03-09 |
| WO2004037984A2 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE485366T1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
| Chay et al. | A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines | |
| Guinea-Viniegra et al. | Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17 | |
| WO2003089457A3 (en) | Peptide inhibitors of protein kinase c ϝ for pain management | |
| DE60233574D1 (de) | Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen | |
| ATE313634T1 (de) | Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose | |
| DE60318900D1 (de) | Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose | |
| DE602004017426D1 (de) | Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression | |
| DE60130797D1 (de) | Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose | |
| IL149922A (en) | Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist | |
| DE60330266D1 (de) | Verfahren zur beurteilung der wirksamkeit von chemotherapeutika | |
| ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| IL179441A (en) | Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme | |
| ATE275919T1 (de) | Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen | |
| DeTemple et al. | Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes | |
| ATE466938T1 (de) | Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs | |
| ATE506073T1 (de) | Verfahren zur modulation der angiogenese mittels der tyrosin kinase src | |
| DE602004030824D1 (de) | An der oberfläche befindliche campylobacter jejuni-polypeptide | |
| DE60130565D1 (de) | Pde8a und seine verwendung | |
| Denhardt | Osteopontin expression correlates with melanoma invasion | |
| Chua et al. | Upregulation of endothelin-1 production by lysophosphatidic acid in rat aortic endothelial cells | |
| DE69635925D1 (de) | Verfahren und testsatz zur evaluierung der metastasierungstendenz von tumoren | |
| ATE543429T1 (de) | Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür | |
| Ikebe et al. | NF-κB involvement in tumor–stroma interaction of squamous cell carcinoma | |
| ATE422896T1 (de) | Eg-vegf/prokineticin 2 rezeptor antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |